Clinical Trial Update: The Use of RAD001 With Docetaxel in the Treatment of Metastatic, Androgen Independent Prostate Cancer [Phase 1, Phase 2]

View source ↗

Summary

A Phase 1/2 study evaluated the combination of everolimus (RAD001) with docetaxel in metastatic castration-resistant prostate cancer; the trial completed and re…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Castration-resistant Prostate Cancer
• Prostate Cancer

Drugs mentioned

• DOCETAXEL (DOCETAXEL)
• Everolimus (everolimus)

Snippet

Sponsor: Dana-Farber Cancer Institute | Conditions: Metastatic, Androgen Independent Prostate Cancer, Prostate Cancer | Phase 1, Phase 2 | Status: COMPLETED | Results posted: 2014-03-03